Cost of behavioral interventions utilizing electronic drug monitoring for antiretroviral therapy adherence

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 1, 2013, Pages

  Rasu, Rafia S ^a   Malewski, David F ^b   Banderas, Julie W ^c   Malomo Thomson, Domonique ^a   Goggin, Kathy ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

adherence; ART; behavioral intervention; cost analysis; economic evaluation; EDM; HIV

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; COST CONTROL; COST UTILITY ANALYSIS; DRUG MONITORING; ECONOMIC EVALUATION; ELECTRONIC DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS;

ADULT; BEHAVIOR THERAPY; COST-BENEFIT ANALYSIS; COUNSELING; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; TREATMENT OUTCOME;

EID: 84876292934     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318285d951     Document Type: Article

References (54)

1. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41:194-200.
2. Jones J, Taylor B, Wilkin TJ, et al. Advances in antiretroviral therapy. Top HIV Med. 2007;15:48-83.
3. Ortego C, Huedo-Medina TB, Llorca J, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav. 2011;15: 1381-1396.
4. Sethi AK. Adherence and HIV drug resistance. HIV Clin Trials. 2004;5: 112-115.
5. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
6. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357-366.
7. Lima VD, Bangsberg DR, Harrigan PR, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr. 2010;55:460-465.
8. Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, the Netherlands, Canada and Australia Study. JAMA. 1995;279:930-937.
9. Race E, Dam E, Obry V, et al. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS. 1999;13:2061-2068.
10. Tilghman M, May S, rez-Santiago J, et al. A combined screening platform for HIV treatment failure and resistance. PLoS One. 2012;7:e35401.
11. Tan J, Sonecha S, Mandalia S, et al. A survey of patients' willingness to switch from a single-tablet regimen to 2 pills once a day as a cost-saving strategy. J Int AIDS Soc. 2012;15:18388.
12. Snedecor S, Khachatryan A, Nedrow K, et al. The prevalence and economic burden of 1st-generation NNRTI resistance. J Int AIDS Soc. 2012; 15:18204.
13. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006;41:285-297.
14. Simoni JM, Amico KR, Smith L, et al. Antiretroviral adherence interventions: translating research findings to the real world clinic. Curr HIV/AIDS Rep. 2010;7:44-51.
15. Hart JE, Jeon CY, Ivers LC, et al. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr. 2010;54:167-179.
16. Hill S, Kavookjian J. Motivational interviewing as a behavioral intervention to increase HAART adherence in patients who are HIV-positive: a systematic review of the literature. AIDS Care. 2012;24:583-592.
17. Ford N, Nachega JB, Engel ME, et al. Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomized clinical trials. Lancet. 2009;374:2064-2071.
18. Simoni JA, Pearson CR, Panalone DW, et al. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. J Acquir Immune Defic Syndr. 2006:43;S23-S35.
19. Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003;115:632-641.
20. Munakata J, Benner JS, Becker S, et al. Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus. Med Care. 2006;44:893-899.
21. Schackman BR, Finkelstein R, Neukermans CP, et al. The cost of HIV medication adherence support interventions: results of a cross-site evaluation. AIDS Care. 2005;17:927-937.
22. Freedberg KA, Hirschhorn LR, Schackman BR, et al. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;43(suppl 1): S113-S118.
23. Bangsberg D, Mundy L, Tulsky J. Expanding directly observed therapy: tuberculosis to human immunodeficiency virus. Am J Med. 2001;110: 664-666.
24. de Bruin M, Hospers HJ, van den Borne HW, et al. Theory-and evidence-based intervention to improve adherence to antiretroviral therapy among HIV-infected patients in the Netherlands: a pilot study. AIDS Patient Care STDS. 2005;19:384-394.
25. de Bruin M, Hospers HJ, van Breukelen GJ, et al. Electronic monitoring-based counseling to enhance adherence among HIV-infected patients: a randomized controlled trial. Health Psychol. 2010;29:421-428.
26. DiIorio C, McCarty F, Resnicow K, et al. Using motivational interviewing to promote adherence to antiretroviral medications: a randomized controlled study. AIDS Care. 2008;20:273-283.
27. Goggin K, Liston RJ, Mitty JA. Modified directly observed therapy for antiretroviral therapy: a primer from the field. Public Health Rep. 2007; 122:472-481.
28. Flanigan TP, Taylor LE, Mitty JA. Use of community-based, directly observed therapy for HIV infection: lessons learned for treatment of hepatitis C virus infection. Clin Infect Dis. 2005;40(suppl 5):S346-S348.
29. Hart JE, Jeon CY, Ivers LC, et al. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr. 2010;54:167-179.
30. Macalino GE, Hogan JW, Mitty JA, et al. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS. 2007;21:1473-1477.
31. Mitty JA, Macalino GE, Bazerman LB, et al. The use of community-based modified directly observed therapy for the treatment of HIV-in-fected persons. J Acquir Immune Defic Syndr. 2005;39:545-550.
32. Mitty JA, Huang D, Loewenthal HG, et al. Modified directly observed therapy: sustained self-reported adherence and HIV health status. AIDS Patient Care STDS. 2007;21:897-899.
33. Smith SR, Rublein JC, Marcus C, et al. A medication self-management program to improve adherence to HIV therapy regimens. Patient Educ Couns. 2003;50:187-199.
34. Sorensen JL, Mascovich A, Wall TL, et al. Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care. 1998;10:297-312.
35. Tuldra A, Fumax CR, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;25:221-228.
36. Weber R, Christen L, Christen S, et al. Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial. Antivir Ther. 2004;9:85-95.
37. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33: 1417-1423.
38. Deschamps AE, de Graeve VD, van Wijngaerden E, et al. Prevalence and correlated of nonadherence to antiretroviral therapy in a population of HIV patients using medication event monitoring system. AIDS Patient Care STDS. 2004;18:644-657.
39. Farley J, Hines S, Musk A, et al. Assessment of adherence to antiviral therapy in HIV-infected children using the medication event monitoring system pharmacy refill, provider assessment, caregiver self-report, and appointment keeping. J Acquir Immune Defic Syndr. 2003;33: 211-218.
40. Müller AD, Bode S, Myer L, et al. Electronic measurement of adherence to pediatric antiretroviral therapy in south Africa. Ped Infect Dis J. 2008; 27:257-262.
41. Rigsby MO, Rosen MI, Beauvais JE, et al. Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med. 2000;15:841-847.
42. Hughes D. When drugs don't work: economic assessment of enhancing compliance with interventions supported by electronic monitoring devices. Pharmacoeconomics. 2007;25:621-635.
43. Goggin K, Gerkovich MM, Williams K, et al. A RCT examining the efficacy of motivational counseling with observed therapy for ART adherence. AIDS and Behavior. 2013; In Press.
44. Drummond MF, O'Brien BJ, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford, United Kingdom: Oxford University Press; 1997.
45. Edejer TT-T, World Health Organization. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva, Switzerland: World Health Organization; 2003.
46. Franzini L, Boom J, Nelson C. Cost-effectiveness analysis of a practice-based immunization education intervention. Ambul Pediatr. 2007;7:167-175.
47. Rasu RS, Hunter CM, Peterson AL, et al. Economic evaluation of an internet-based weight management program. Am J Manag Care. 2010; 16:e98-e104.
48. Rianon N, Selwyn B, Shahidullah S, et al. Cost of health education to increase STD awareness in female garment workers in Dhaka, Bangladesh. Int Electron J Health Educ. 2009;12:135-149.
49. HIV Cost and Services Utilization Study. Public Use Interview Data Set. Rockville, MD: Agency for Health Care Research and Quality; 2000.
50. US Department of Labor Bureau of Labor Statistics. National compensation survey. Available at: http://data.bls.gov. Accessed March 28, 2010.
51. Liu H, Wilson IB, Goggin K, et al. MACH14: a multi-site collaboration on ART adherence among 14 institutions. AIDS Behav. 2012: DOI 10.1007/s10461-012- 0272-4.
52. Blaschke TF, Osterberg L, Vrijens B, et al. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012;52: 275-301.
53. McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis. 2011; 52:493.
54. Rosen MI, Dieckhaus K, McMahon TJ, et al. Improved adherence with contingency management. AIDS Patient Care STDs. 2007;21:30-40.